Study Title | A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy |
---|---|
Protocol ID | Firefly-2 |
Disease (Sub Disease) | Low-Grade Glioma |
Diagnosis Stage | Newly diagnosed |
Sponsor | Day One Biopharmaceuticals, Inc. |
Collaborators | SIOPe Brain Tumor Group LOGGIC Consortium |
Links | https://clinicaltrials.gov/ct2/show/NCT05566795 |
Trial Status | Preparing to Open |
Study Type | Treatment |
Phase | Phase 3 |
Age Eligibility | up to 25 Years |
International registry ID's | NCT05566795 |